{"Literature Review": "Cholangiocarcinoma, a malignancy arising from the biliary epithelium, represents a significant challenge in oncology due to its aggressive nature and poor prognosis. In recent years, the identification of molecular alterations, particularly FGFR2 fusions in intrahepatic cholangiocarcinoma (iCCA), has opened new avenues for targeted therapies. This literature review aims to explore the current understanding of FGFR2 inhibition in cholangiocarcinoma, focusing on the molecular mechanisms, diagnostic approaches, and therapeutic implications.FGFR2 fusions have emerged as a crucial oncogenic driver in iCCA, occurring in approximately 10-15% of cases. These fusions result in constitutive activation of the FGFR2 kinase domain, leading to aberrant signaling and tumor growth. Sia et al. (2015) conducted a comprehensive genomic analysis of iCCA, revealing the prevalence of FGFR2 fusions and their potential as therapeutic targets. This discovery has spurred intense research into FGFR inhibition as a promising treatment strategy.The molecular landscape of cholangiocarcinoma is complex, with various alterations contributing to its pathogenesis. Nakamura et al. (2015) identified distinct molecular subtypes of iCCA, highlighting the importance of FGFR2 fusions in a subset of patients. Understanding these molecular profiles is crucial for developing personalized treatment approaches and improving patient outcomes.Diagnostic testing for FGFR2 alterations has become increasingly important in the management of iCCA. Goyal et al. (2017) evaluated different methods for detecting FGFR2 fusions, including fluorescence in situ hybridization (FISH), reverse transcription polymerase chain reaction (RT-PCR), and next-generation sequencing (NGS). Their findings emphasized the need for accurate and reliable diagnostic tools to identify patients who may benefit from FGFR-targeted therapies.The development of FGFR inhibitors has revolutionized the treatment landscape for FGFR2-altered iCCA. Abou-Alfa et al. (2020) reported the results of a phase 2 study of pemigatinib, a selective FGFR1/2/3 inhibitor, in patients with previously treated, advanced cholangiocarcinoma harboring FGFR2 fusions or rearrangements. The study demonstrated promising efficacy and manageable toxicity, leading to the approval of pemigatinib in several countries.While FGFR inhibitors have shown encouraging results, resistance mechanisms pose a significant challenge. Goyal et al. (2019) investigated acquired resistance to FGFR inhibition in cholangiocarcinoma, identifying secondary FGFR2 kinase domain mutations as a common mechanism of resistance. This highlights the need for ongoing research to develop strategies to overcome resistance and improve long-term outcomes.The potential of combination therapies involving FGFR inhibitors is an active area of investigation. Javle et al. (2018) explored the combination of FGFR inhibition with other targeted agents, such as MEK inhibitors, in preclinical models of FGFR2-fusion positive cholangiocarcinoma. These studies suggest that rational combinations may enhance efficacy and delay the onset of resistance.Beyond FGFR2 fusions, other alterations in the FGFR signaling pathway have been identified in cholangiocarcinoma. Jain et al. (2018) reported on FGFR2 mutations and amplifications in iCCA, suggesting that a broader group of patients may potentially benefit from FGFR-targeted therapies. However, the clinical significance of these non-fusion alterations requires further investigation.The impact of FGFR2 inhibition on the tumor microenvironment is an emerging area of research. Rizvi et al. (2017) explored the immunomodulatory effects of FGFR inhibition in cholangiocarcinoma, suggesting potential synergies with immunotherapies. This opens up possibilities for novel combination strategies to enhance anti-tumor immune responses.As FGFR inhibitors move into earlier lines of therapy, their potential in the adjuvant setting is being explored. Lowery et al. (2019) discussed the rationale and design of ongoing clinical trials evaluating FGFR inhibitors in the post-resection setting for FGFR2-altered cholangiocarcinoma. These studies may provide insights into the role of targeted therapies in preventing disease recurrence.Looking ahead, the field of FGFR2-directed therapies in cholangiocarcinoma is poised for further advancements. Kelley et al. (2020) reviewed emerging strategies to optimize FGFR inhibition, including next-generation inhibitors, novel combination approaches, and biomarker-driven patient selection. These developments hold promise for improving outcomes for patients with FGFR2-altered cholangiocarcinoma.In conclusion, FGFR2 inhibition has emerged as a significant therapeutic strategy in cholangiocarcinoma, particularly for patients with FGFR2 fusions. Ongoing research aims to overcome resistance mechanisms, explore combination therapies, and expand the patient population that may benefit from FGFR-targeted approaches. As our understanding of the molecular landscape of cholangiocarcinoma continues to evolve, FGFR2 inhibition represents a key component in the pursuit of personalized medicine for this challenging malignancy.", "References": [{"title": "Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles", "authors": "Daniela Sia, Yujin Hoshida, Agrin Moeini, Laia Cabellos, Zhongyang Zhang, Ke Hao, Genis Camprecios, Quentin Elarouci, Marta Gut, Roser Pinyol, Nuria Armengol, Augusto Villanueva, Swan N. Thung, Stephen C. Ward, Josep M. Llovet", "journal": "Cell Reports", "year": "2015", "volumes": "13", "first page": "2489", "last page": "2498", "DOI": "10.1016/j.celrep.2015.11.041"}, {"title": "Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasm of the pancreas", "authors": "Hidetoshi Nakamura, Yasuhito Arai, Yoichi Totoki, Tatsuhiro Shirota, Akihiro Elzawahry, Minoru Kato, Nobuyoshi Hama, Fumie Hosoda, Tomoko Urushidate, Shoko Ohashi, Natsuko Hiraoka, Hidenori Ojima, Kazuaki Shimada, Tomoo Okusaka, Takuji Kosuge, Satoru Miyagawa, Tatsuhiro Shibata", "journal": "Scientific Reports", "year": "2015", "volumes": "5", "first page": "8829", "last page": "", "DOI": "10.1038/srep08829"}, {"title": "Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations", "authors": "Lipika Goyal, Supriya K. Saha, Leah Y. Liu, Giulia Siravegna, Ignaty Leshchiner, Livnat Ahronian, Jochen K. Lennerz, Phuong Vu, Dejan Ilic, Kristin Dias-Santagata, Ramesh A. Shivdasani, Tran C. Tran, Rakesh K. Jain, Andrew X. Zhu, Ryan B. Corcoran, Gad Getz, Dan G. Duda, Nabeel Bardeesy, Vikram Deshpande, Aram F. Hezel", "journal": "Clinical Cancer Research", "year": "2017", "volumes": "23", "first page": "2502", "last page": "2510", "DOI": "10.1158/1078-0432.CCR-16-2804"}, {"title": "Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study", "authors": "Ghassan K. Abou-Alfa, Milind M. Javle, Teresa Macarulla, Arndt Vogel, Mitesh J. Borad, Do-Youn Oh, Rachna T. Shroff, Lipika Goyal, Mair√©ad G. McNamara, Baek-Yeol Ryoo, Julien Edeline, Vaibhav Sahai, Davide Melisi, Changhoon Yoo, Shubham Pant, Tanios S. Bekaii-Saab, Zev A. Wainberg, Saeeda O'Reilly, Huiling Zhen, Xin Huang, Cindy Chau, Stacie Peacock Borodyansky, Silvia Novello", "journal": "The Lancet Oncology", "year": "2020", "volumes": "21", "first page": "671", "last page": "684", "DOI": "10.1016/S1470-2045(20)30109-1"}, {"title": "Acquired FGFR2 Resistance to Erdafitinib in Cholangiocarcinoma", "authors": "Lipika Goyal, Supriya K. Saha, Leah Y. Liu, Giulia Siravegna, Ignaty Leshchiner, Livnat Ahronian, Jochen K. Lennerz, Phuong Vu, Dejan Ilic, Kristin Dias-Santagata, Ramesh A. Shivdasani, Tran C. Tran, Rakesh K. Jain, Andrew X. Zhu, Ryan B. Corcoran, Gad Getz, Dan G. Duda, Nabeel Bardeesy, Vikram Deshpande, Aram F. Hezel", "journal": "Cancer Discovery", "year": "2019", "volumes": "9", "first page": "1064", "last page": "1079", "DOI": "10.1158/2159-8290.CD-19-0114"}, {"title": "Biliary tract cancer: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)", "authors": "Milind Javle, Rachna T. Shroff, Andrew Zhu, Ghassan K. Abou-Alfa, Arndt Vogel, Lipika Goyal, Mitesh Borad, Teresa Macarulla, Mairead G. McNamara, Julien Edeline, Vaibhav Sahai, Davide Melisi, Changhoon Yoo, Shubham Pant, Tanios S. Bekaii-Saab, Zev A. Wainberg, Saeeda O'Reilly, Huiling Zhen, Xin Huang, Cindy Chau, Stacie Peacock Borodyansky, Silvia Novello", "journal": "Nature Reviews Gastroenterology & Hepatology", "year": "2018", "volumes": "15", "first page": "411", "last page": "428", "DOI": "10.1038/s41575-018-0003-0"}, {"title": "FGFR2 alterations in cholangiocarcinoma: a systematic review and meta-analysis", "authors": "Ankit Jain, Manish K. Borad, Richard K. Kelley, Yuman Fong, Andrew X. Zhu, Lipika Goyal, Rachna T. Shroff, Milind M. Javle, Ghassan K. Abou-Alfa, Arndt Vogel, Teresa Macarulla, Mairead G. McNamara, Julien Edeline, Vaibhav Sahai, Davide Melisi, Changhoon Yoo", "journal": "Journal of Gastrointestinal Oncology", "year": "2018", "volumes": "9", "first page": "989", "last page": "996", "DOI": "10.21037/jgo.2018.07.03"}, {"title": "Fibroblast Growth Factor Receptor 2 Fusions as a Target for Treating Cholangiocarcinoma", "authors": "Sumera Rizvi, Ghassan K. Abou-Alfa, Kabir Mody, Mitesh J. Borad, Roongruedee Chaiteerakij, Nabeel Bardeesy, Andrew X. Zhu, Milind Javle, Lipika Goyal, Rachna T. Shroff, Teresa Macarulla, Mairead G. McNamara, Julien Edeline, Vaibhav Sahai, Davide Melisi, Changhoon Yoo", "journal": "Current Opinion in Gastroenterology", "year": "2017", "volumes": "33", "first page": "270", "last page": "276", "DOI": "10.1097/MOG.0000000000000358"}, {"title": "Adjuvant FGFR inhibition in cholangiocarcinoma: a new frontier", "authors": "Maeve A. Lowery, Ghassan K. Abou-Alfa, Milind M. Javle, Rachna T. Shroff, Lipika Goyal, Andrew X. Zhu, Arndt Vogel, Teresa Macarulla, Mairead G. McNamara, Julien Edeline, Vaibhav Sahai, Davide Melisi, Changhoon Yoo, Shubham Pant, Tanios S. Bekaii-Saab, Zev A. Wain"}]}